Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Vera Therapeutics ( (VERA) ).
On March 5, 2026, Vera Therapeutics, Inc. appointed Christopher Hite to its board of directors as a Class III director, with his initial term running through the 2027 annual meeting of stockholders. As part of his compensation, Hite received a nonstatutory stock option to purchase 24,937 shares of Class A common stock at an exercise price of $38.85 per share, which will vest monthly over three years, alongside a pro-rated $45,000 cash retainer for 2026.
Beginning with the 2027 annual meeting, Hite will be eligible for additional annual option grants subject to value and share caps, with each grant vesting on the earlier of one year from grant or the next annual meeting, conditional on continued service. The company noted that Hite will sign its standard indemnification agreement and that there were no preexisting arrangements or related-party transactions tied to his selection, underscoring a conventional and independent director appointment process for shareholders.
The most recent analyst rating on (VERA) stock is a Buy with a $110.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Neutral.
The score is held back primarily by accelerating losses and cash burn despite a relatively strong, low-leverage balance sheet. Technicals are weak near term (below key short-term moving averages with negative MACD), while the recent equity raise modestly improves financial flexibility but also underscores reliance on external funding.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Vera Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for serious diseases, operating in a highly regulated, research-driven segment of the healthcare industry. The company’s governance structure includes a classified board of directors, reflecting common practices among growth-stage biotech and pharma issuers.
Average Trading Volume: 1,160,234
Technical Sentiment Signal: Buy
Current Market Cap: $2.79B
For an in-depth examination of VERA stock, go to TipRanks’ Overview page.